Ocugen’s GA gene therapy shows potential edge over rivals in early phase 2 data
Ocugen reports preliminary phase 2 data for OCU410 to treat geographic atrophy (GA) from dry AMD, with the medium dose showing a 54% reduction in lesion growth vs placebo at 12 months and the high dose 36% in a small patient subset, raising questions about dose response; Ocugen aims to present full data this quarter and move to phase 3 by year-end, targeting an FDA filing in 2028, and argues the therapy could outperform Apellis' Syfovre and Astellas' Izervay.
